Sunitinib for Patients with Metastatic Non-clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Turkish Oncology Group Trial

Basit Öğe Kaydı
dc.contributor.authorYildiz, Ibrahim
dc.contributor.authorEkenel, Meltem
dc.contributor.authorAkman, Tulay
dc.contributor.authorKocar, Muharrem
dc.contributor.authorUysal, Mukremin
dc.contributor.authorKanitez, Metin
dc.contributor.authorVarol, Umut
dc.date.accessioned2024-04-24T17:38:10Z
dc.date.available2024-04-24T17:38:10Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractAim: This study aimed to assess the clinical efficacy and toxicity of sunitinib, a targeted-agent, for non-clear cell renal cell carcinoma. Patients and Methods: Sixty-three patients with complete clinical data from 13 oncology Centers were retrospectively evaluated. Outcomes analyzed were objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and adverse events. Results: The median age of all patients, 38 men (60.3%) and 25 women (39.7%), was 63 years (range=25-82 years). Histological subtypes included 46 (88%) cases of papillary RCC, 10 of chromophobe, and 7 unclassified cases. Median treatment duration was seven months (range=2-86 months). At the time of this analysis, 52 patients had discontinued treatment, 33 of whom had died. Treatment discontinuation was due to disease progression in 43 patients, and toxicity in nine. Dose interruption was necessary in 22 (34.9%) patients, and dose reduction in 27 (42.9%). The objective response rate and disease control rate were 11.1% and 63.5%, respectively. The median PFS and OS were 7.6 months (95% confidence interval (CI)=5.5-9.7 months) and 22.0 months (95% CI=13.4-30.6 months), respectively, with 1-year rates of 64.7% and 33.7%, respectively. Conclusion: Clinical outcome of the metastatic non-clear cell RCC patients with sunitinib treatment seemed to be worse than the historical data of clear cell RCC patients, in terms of PFS, OS and objective response. New and more effective targeted-therapies and better understanding of the underlying molecular processes are necessary to improve survival outcome for these patients.en_US
dc.identifier.endpage4334en_US
dc.identifier.issn0250-7005
dc.identifier.issn1791-7530
dc.identifier.issue8en_US
dc.identifier.pmid25075067
dc.identifier.scopus2-s2.0-84909959555
dc.identifier.scopusqualityQ3
dc.identifier.startpage4329en_US
dc.identifier.urihttps://hdl.handle.net/11468/21352
dc.identifier.volume34en_US
dc.identifier.wosWOS:000339773400061
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherInt Inst Anticancer Researchen_US
dc.relation.ispartofAnticancer Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdverse Effectsen_US
dc.subjectMetastatic Non-Clear Cell Renal Cell Carcinomaen_US
dc.subjectSunitiniben_US
dc.titleSunitinib for Patients with Metastatic Non-clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Turkish Oncology Group Trialen_US
dc.titleSunitinib for Patients with Metastatic Non-clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Turkish Oncology Group Trial
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu